about
HIV-Host Interactions: Implications for Vaccine DesignImmune correlates of vaccine protection against HIV-1 acquisitionDesigning synthetic vaccines for HIVA saposin-lipoprotein nanoparticle system for membrane proteins.Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic AntibodyHumanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman PrimatesHumoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionRedemption of autoreactive B cells.DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titersCharacterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein BoostA critical question for HIV vaccine development: which antibodies to induce?A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy.Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortImmunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles.Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.Analysis of IgM antibody production and repertoire in a mouse model of Sjögren's syndrome.New approaches to HIV vaccine development.Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies.What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling.The quest for an antibody-based HIV vaccine.HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism.Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.Cross-reactivity of HIV vaccine responses and the microbiome.HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes
P2860
Q26765966-85B6E4BA-00DE-4961-9986-673B437F3961Q26778573-551FD1D7-C17B-4FF9-AB92-25E6CD6A73ACQ26862617-704A616F-2A9E-43D8-9165-6B50F2907623Q27313390-70CA35D7-E245-4929-98B3-F7B5A777D485Q27644415-F875EFA7-22E6-4249-91BB-4FBF134393C6Q30234773-2285BBA0-2A15-4C82-9321-49159AC1DA4AQ33612459-E36A3136-305A-4E91-A096-F776050EFF2EQ33620546-4190DCFE-B777-4D2A-B6D2-AB8A4C06980FQ33835034-839761E2-D565-4013-A86F-5FBCC31A7C35Q35640984-9AD7829C-6AA5-429D-B46D-49F36972B207Q35651494-4213BC69-98DC-42E2-976B-3A25A10EFAF1Q35728947-4C1817FD-5BC9-4349-BD82-99745FD299AFQ35760486-3F4251DE-5997-4828-8517-06A074622B46Q35783015-D08A4E1B-0A95-4237-90CC-A5A47C9CFA3BQ35825170-7D4A454A-9268-49C0-9181-D2BF3A2CBF04Q35894094-2523A7DF-00BF-42D9-BFA6-A88A1A55FD8BQ35960908-9563B101-015D-4962-90E1-74755098C74CQ36446733-2575C372-9DCF-426E-8715-5966827A8D11Q36477926-0FD2BAAB-58AE-4B8F-A7AA-DB6026E44452Q38521826-D16BBE1C-9977-4D4A-86B2-0CF715B721A2Q38747466-7D502CB2-31B5-4ECA-8C91-048289377D13Q40103798-51D9781D-F80A-4976-B952-25C7C0F7B517Q40166335-013FA27F-CD2C-4B86-863F-B5708A4DDF55Q40354016-69EEC115-8947-42B2-8627-4E5E96BA2730Q40449984-33AAEB28-FEE3-4D20-ADD6-741E8089D528Q47118310-C1F0C975-D2DA-485C-B390-CC1AE70A3EE5Q47215738-9A5209C9-E5D1-4C6B-B543-E1617DCFD74CQ47611203-54EA4EC1-F62C-452B-9FED-98F82F4C0644Q56913214-69E4778C-BB6E-4045-948A-E69BEC16482A
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
AIDS/HIV. Host controls of HIV neutralizing antibodies.
@ast
AIDS/HIV. Host controls of HIV neutralizing antibodies.
@en
AIDS/HIV. Host controls of HIV neutralizing antibodies.
@nl
type
label
AIDS/HIV. Host controls of HIV neutralizing antibodies.
@ast
AIDS/HIV. Host controls of HIV neutralizing antibodies.
@en
AIDS/HIV. Host controls of HIV neutralizing antibodies.
@nl
prefLabel
AIDS/HIV. Host controls of HIV neutralizing antibodies.
@ast
AIDS/HIV. Host controls of HIV neutralizing antibodies.
@en
AIDS/HIV. Host controls of HIV neutralizing antibodies.
@nl
P2860
P356
P1433
P1476
AIDS/HIV. Host controls of HIV neutralizing antibodies.
@en
P2093
Laurent Verkoczy
P2860
P304
P356
10.1126/SCIENCE.1254990
P407
P577
2014-05-01T00:00:00Z